Results 101 to 110 of about 340,370 (339)

Existing and emerging therapies for the treatment of familial hypercholesterolemia

Journal of Lipid Research, 2021
Familial hypercholesterolemia (FH), an autosomal dominant disorder of LDL metabolism that is characterized by elevated LDL-cholesterol, is commonly encountered in patients with atherosclerotic coronary heart disease.
R. Rosenson
semanticscholar   +1 more source

The panorama of familial hypercholesterolemia in Latin America: a systematic review[S]

Journal of Lipid Research, 2016
The burden caused by familial hypercholesterolemia (FH) varies among countries and ethnic groups. The prevalence and characteristics of FH in Latin American (LA) countries is largely unknown. We present a systematic review (following the PRISMA statement)
Roopa Mehta, Rafael Zubirán, Alexandro J. Martagón, Alejandra Vazquez-Cárdenas, Yayoi Segura-Kato, María Teresa Tusié-Luna, Carlos A. Aguilar-Salinas   +6 more
doaj   +1 more source

A high‐fat diet with vitamin D and propylthiouracil produces a pro‐atherogenic phenotype in rats

Animal Models and Experimental Medicine, EarlyView.
Male Sprague–Dawley rats received a cholesterol‐rich high‐fat diet supplemented with vitamin D and propylthiouracil for 11 weeks. The model induced dyslipidemia (increased total cholesterol/low‐density lipoprotein, decreased triglycerides), inflammation (increased interleukin‐6 and serum amyloid A), hypercalcemia, and reduced circulating endothelial ...
Angélique Lewies, Vitaris Kodogo, Johannes Frederik Wentzel, Francis Edwin Smit   +3 more
wiley   +1 more source

Molecular basis of familial hypercholesterolemia

, 2017
Purpose of review To provide an overview about the molecular basis of familial hypercholesterolemia. Recent findings Familial hypercholesterolemia is a common hereditary cause of premature coronary heart disease. It has been estimated that 1 in every 250
Hovingh, Gerard K., Gerard K. Hovingh, Caroline S. Bruikman, Bruikman, Caroline S., John J.P. Kastelein, Kastelein, John J. P.   +5 more
core   +1 more source

Recent advances in the construction of humanized animal models and applications in translational medicine

Animal Models and Experimental Medicine, EarlyView.
Substantial advances have been achieved in the development of humanized mouse models, which have proven highly valuable in evaluating cancer immunotherapies and elucidating the mechanisms of infectious diseases. There is now a growing shift in research toward larger animal models—such as pigs—that offer greater physiological similarity to humans ...
Yanan Lyu, Yong‐Guang Yang, Zheng Hu
wiley   +1 more source

Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.

New England Journal of Medicine, 2020
BACKGROUND Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin-kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels.
R. Santos, A. Ruzza, G. Hovingh, A. Wiegman, F. Mach, C. Kurtz, A. Hamer, I. Bridges, A. Bartuli, J. Bergeron, T. Szamosi, S. Santra, C. Stefanutti, O. Descamps, S. Greber-Platzer, I. Luirink, J. Kastelein, D. Gaudet, Hauser-Rct Investigators   +18 more
semanticscholar   +1 more source

A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated With Colchicine Prophylaxis

Arthritis &Rheumatology, EarlyView.
Objective This study investigated that serum metabolomics, before urate‐lowering therapy (ULT) initiation, could serve as a biomarker for responsiveness to colchicine prophylaxis in patients with gout commencing treat‐to‐target ULT. Methods We studied a multicenter prospective cohort (n = 409) initiating treat‐to‐target ULT plus colchicine prophylaxis.
Wenyan Sun, Lingfang Xu, Haibing Chen, Mingshu Sun, Zhiqiang Li, Rui Li, Lidan Ma, Hui Zhang, Aichang Ji, Yuwei He, Na Wu, Le Yan, Robert Terkeltaub, Changgui Li   +13 more
wiley   +1 more source

Next-generation sequencing to confirm clinical familial hypercholesterolemia

, 2021
BACKGROUND: Familial hypercholesterolemia is characterised by high low-density lipoprotein-cholesterol levels and is caused by a pathogenic variant in LDLR, APOB or PCSK9.
Reeskamp, Laurens F., Defesche, Joep C., Hovingh, G. Kees, Zuurbier, Linda, Grefhorst, Aldo, Tromp, Tycho R., Stroes, Erik S. G.   +6 more
core   +1 more source

Prescribing competence: The pros and cons of different methods for assessment

British Journal of Clinical Pharmacology, EarlyView.
Evaluating a medical graduate’s competence in rational prescribing is challenging. With the aim to guide and inspire teachers, this narrative review explores different methods that can be used to assess prescribing competence. Each method has its own advantages and disadvantages, and thus a mix of different assessment methods is needed throughout the ...
David J. Brinkman, Erik M. Donker, Jelle Tichelaar, on behalf of the CP4T programme   +3 more
wiley   +1 more source

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia.

Journal of the American College of Cardiology, 2020
BACKGROUND Proprotein convertase subtilisin/kexin type 9 inhibitor therapy is a treatment option for patients with familial hypercholesterolemia (FH) who are unable to reach low-density lipoprotein cholesterol (LDL-C) goals.
Raul D. Santos, E. Stein, G. Hovingh, D. Blom, H. Soran, G. Watts, J. A. López, S. Bray, C. Kurtz, A. Hamer, F. Raal   +10 more
semanticscholar   +1 more source